$ cat ./records/gates-foundation-partners-with-inovio-on-ebola-dna-vaccine-and-ce-2014.txt
Gates Foundation Partners with Inovio on Ebola DNA Vaccine and CELLECTRA Platform
[RECORD.TXT] · cat --full
The Gates Foundation provided $5 million to Inovio Pharmaceuticals to accelerate development of the INO-4201 DNA vaccine targeting Zaire Ebola virus and to advance Inovio's CELLECTRA electroporation delivery device, which enhances uptake of DNA vaccine constructs. In clinical studies, Inovio's Ebola vaccine demonstrated 100 percent immunogenicity. The investment also supported Inovio's broader infectious disease platform spanning HIV, Zika, and MERS, positioning electroporation as a technology Gates considered critical for rapid vaccine deployment in outbreak settings.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Funds Ebola Health Worker Training Across West Africa
Next →
Gates Foundation Backs Sabin Vaccine Institute to Develop ChAd3 Ebola Vaccine
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.